A Single Agent Study to Evaluate the Overall Response Rate, Safety and Tolerability of Orally Administered Vemurafenib

NCT02115035 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Funding issues

Conditions

Multiple Myeloma

Interventions

DRUG: Vermurafenib

Sponsor

University of Arkansas